← Eichor
Study identifier: NCT02215928 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Genomic Profiling in Recommending Treatment for Patients With Metastatic Solid Tumors

Condition: Unspecified Adult Solid Tumor, Protocol Specific  ·  Sponsor: Stanford University

PhaseN/A
Planned participants100
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This research trial studies using genomic profiling to recommend anticancer treatment to patients with cancer that has spread beyond the original site of the tumor (metastatic cancer). Genomic profiling studies the deoxyribonucleic acid (DNA) of a tumor to detect genetic changes or abnormalities. This information can then be used to recommend treatments that may be more likely to result in a beneficial response. It is not yet known whether genomic profiling will detect abnormalities that can be used to make treatment recommendations and whether treatment based on genomic profiling is more effective than standard treatment.

This description comes directly from the study's public registry record.

Talk to the study team

Rozelle Laquindanum  ·  (650) 724-9948  ·  rlaquind@stanford.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Stanford UniversityPalo Alto, California, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT02215928